


**REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/US03/09225 into the U.S. National Phase of prosecution. In the specification, a new paragraph has been added to the first line of the specification to include the priority information. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Claims 7-15 have been amended to remove multiple dependencies, and claims 16-27 have been cancelled without prejudice or disclaimer.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

N:\KLS\Cases\VP51332\NatI Stage\preliminary amendment.doc

P51332

**ABSTRACT OF THE DISCLOSURE**

Disclosed are methods of using compounds that modulate LXR.